Imfinzi Shows Survival Benefits in Small Cell Lung Cancer But Fails Cost-Effectiveness Analysis
核心洞察
A new analysis published in JCO Global Oncology found that Imfinzi (durvalumab) significantly improves survival in limited-stage small cell lung cancer patients but is not cost-effective at current U.S. list prices.
The study showed Imfinzi extended median overall survival to 66.1 months compared to 57.8 months with standard care, but resulted in an incremental cost-effectiveness ratio of $383,069 per quality-adjusted life year.
Researchers from Sylvester Comprehensive Cancer Center (搜索) highlighted the need to align clinical innovation with cost-effectiveness to ensure sustainable adoption in the U.S. healthcare system.
For patients with limited-stage small cell lung cancer (LS-SCLC), a disease long marked by poor outcomes and few treatment advances, immunotherapy has offered renewed hope. However, a new analysis suggests that progress may come at a steep cost, raising critical questions about the sustainability of innovative cancer treatments.
Survival Benefits Come with High Price Tag
In a study published in December 2025 in JCO Global Oncology, researchers from Sylvester Comprehensive Cancer Center (搜索) at the University of Miami report that Imfinzi (durvalumab), used as consolidation therapy after chemoradiation, significantly improves survival but is not cost-effective for most patients with LS-SCLC at current U.S. list prices.
Using a partitioned survival model, the researchers compared Imfinzi consolidation therapy with standard of care across three health states and calculated costs per quality-adjusted life year (QALY) gained. The model showed that adding Imfinzi extended median overall survival to 66.1 months and progression-free survival to 40.2 months, compared with 57.8 months and 31.8 months, respectively, for standard therapy.
"While durvalumab delivers meaningful survival benefits in limited-stage small cell lung cancer, our analysis highlights the need to align clinical innovation with cost-effectiveness to ensure sustainable adoption in the U.S. healthcare system," said Chinmay Jani, M.D., the study's lead author and Chief Fellow of Hematology and Oncology at Sylvester Comprehensive Cancer Center (搜索).
Cost-Effectiveness Analysis Reveals Concerning Results
Total treatment costs were estimated at $163,722 for Imfinzi versus $25,816 for standard care, resulting in an incremental cost of nearly $138,000. The resulting incremental cost-effectiveness ratio (ICER) was $383,069 per QALY, which is well above the $150,000 threshold commonly used in the United States.
One notable exception emerged from the analysis. In patients whose disease progressed outside the chest, Imfinzi's ICER fell to $151,137 per QALY, narrowly exceeding the threshold and suggesting potential value in a subset of patients.
Clinical Context and Treatment Landscape
Small cell lung cancer accounts for roughly 15% of lung cancer cases and is linked to heavy smoking. For decades, limited-stage SCLC has been treated with chemotherapy and radiation, with only about 25% to 30% of patients surviving five years. The FDA expanded Imfinzi's indications to include limited-stage SCLC after chemoradiation in December 2024, following positive results from the ADRIATIC trial where the PD-L1 (搜索) inhibitor improved overall survival and progression-free survival.
"Durvalumab represents a turning point in maintenance therapy for SCLC," said Jani. "We're seeing survival gains that were unimaginable just a few years ago."
Implications for Healthcare Policy and Access
The authors note a persistent tension in oncology between therapies that improve survival and their growing economic burden. They found that, under current U.S. pricing, broad use of Imfinzi in LS-SCLC would likely worsen financial toxicity and could further limit access.
"Cost-effectiveness isn't just a metric-it shapes real-world access," said Gilberto Lopes, M.D., chief of the Division of Medical Oncology and associate director for global oncology at Sylvester. "We need strategies that make innovation sustainable."
Editorial Commentary Highlights Pricing Complexities
In an accompanying editorial, Yuchen Li, M.D., M.P.H., and Fabio Ynoe de Moraes, M.D., Ph.D., MBA, of Queen's University in Kingston, Ontario, noted important limitations of the analysis. They pointed out that the study used U.S. list prices that are often much higher than the net prices paid by public and other payers after various discounting, and that U.S. list prices are higher than publicly posted prices in the United Kingdom and Canada.
The editorial authors also emphasized that upfront expenditures on durvalumab need to be seen in the context of averted costs for recurrent or metastatic SCLC, which they described as "resource-intensive, often involving hospitalizations, complex supportive care, and later-line therapies."
Potential Solutions for Improved Access
Li and de Moraes mentioned several steps that might be taken to make Imfinzi more affordable, especially in low- and middle-income countries where the annual cost of durvalumab may exceed a patient's lifetime earnings or an institution's entire oncology budget. These include preliminary data supporting lower doses and longer intervals between doses, regional pooled procurement, tiered pricing, outcomes-based contracts, and nonprofit distribution models.
"As immunotherapy reshapes the standard of care in limited-stage SCLC, integrating cost-effectiveness with clinical benefit will be critical to achieving both improved outcomes and affordability," Jani stated.
The analysis suggests that while Imfinzi represents clinical progress for a historically challenging disease, evolving federal drug price negotiation policies may eventually alter the cost-effectiveness equation. For now, the study highlights the ongoing challenge of balancing clinical innovation with healthcare sustainability.